Dynamk Capital

VC New York, United States · Founded 2016

Dynamk Capital invests in early-stage life science tools, technologies, and services that enable therapeutic discovery, development, and manufacturing. They focus on disruptive technologies that facilitate the entire biopharma continuum, including cell and gene therapies and vaccines.

About Dynamk Capital

Dynamk Capital is a venture capital firm focused on the life sciences industrials and bioprocess technology sector, investing in companies that supply tools, instruments, equipment, and services to the broader biopharma and life sciences industries. The firm has website, LinkedIn, and Crunchbase footprint, with a clearly scoped thesis distinct from generalist healthcare or biotech investors. For healthcare AI founders, Dynamk is a fit only if you are building AI applied to bioprocess optimization, biomanufacturing, life sciences instrumentation, lab automation, biopharma supply chain, or adjacent life sciences industrial categories where the customer is a biopharma or CRO operations or manufacturing function. Founders building clinical software, patient-facing AI, care delivery, or therapeutics themselves are unlikely to find a fit; the thesis is sharply scoped to industrial life sciences. Check sizes typically range from $1M to $5M at Series A and B, with the firm capable of leading rounds and providing deep sector network value. The strongest fit is for healthcare AI companies with credible commercial traction in biopharma manufacturing, lab operations, or life sciences supply chain customer segments. Founders without a life sciences industrial angle should not pursue Dynamk, regardless of how compelling the broader healthcare AI thesis is. The firm’s value-add is exceptional within its mandate, with deep biopharma operating relationships, life sciences industrial customer access, and credibility with industrial-stage follow-on capital. Entry path is LinkedIn outreach to the partners, the website inquiry form, or warm referral from a portfolio CEO or biopharma operator. Founders should come prepared with deep customer references and operational metrics relevant to bioprocess or life sciences manufacturing.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Healthcare AI tools backed by Dynamk Capital

Tools made by companies in Dynamk Capital's portfolio that we cover in the directory.

Loss of Pulse Detection
Fitbit
Cardiology AI
Fitbit's Loss of Pulse Detection is an FDA-cleared feature on compatible wearable devices that uses PPG and accelerometry to detect a potential loss of pulse and can automatically alert emergency services if the user is unresponsive.

Portfolio companies in our directory

Other portfolio companies

Companies in Dynamk Capital's portfolio not currently in our directory.

  • Alpenglow Biosciences · 2021
  • Virica Biotech · 2021
  • RoosterBio
  • Envisagenics · 2017
  • Curi Bio · 2021
  • CellFE Biotech · 2023
  • Xcell Biosciences · 2024
  • Lucid Scientific · 2023
  • Vernal Biosciences · 2023
  • Bionter AG · 2022
  • Savant Labs · 2025

Team

Daniella Kranjac
Founding Partner
Sebastien Latapie
Principal
Reinhard Vogt
Managing Director
Gustavo Mahler
CEO, CMC Biologics / AGC Asahi Glass (Advisor)
Barry Buckland
CEO, BiologicB, LLC (Advisor)
Anthony Maddaluna
Former President, Pfizer Global Supply (Advisor)

Pitch / review this investor

Have you raised from Dynamk Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.